[The half-life of iodine 131-labelled fibrinogen in cancer patients. Effects of heparin].
Sixty nine patients suffering from malignant tumours at different stages of their development underwent a kinetic study of fibrinogen 131I with external counting over the tumour and a study of haemostasis including P.D.F. The 1/2 T of fibrinogen 131I is shortened: 2.52 +/- 0.09 days (normal: 3.89 +/- 0.11 days.) The abnormality is proportional to serum P.D.F. levels (r=0.99). External counting demonstrated the uptake of labelled fibrinogen in the tumour. Heparine (15000 U/24h) restores the 1/2 T of fibrinogen to normal in 95 p. cent of cases. The results suggest the existence of a localised compensated intravascular coagulation process inside the tumour. Possible consequences of that phenomenon are discussed.
D001777:Blood Coagulation / Q000187:drug effects; D001779:Blood Coagulation Factors / Q000378:metabolism; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D006207:Half-Life; D006487:Hemostasis; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D007457:Iodine Radioisotopes; D009369:Neoplasms / Q000378:metabolism*; D011877:Radionuclide Imaging
D001779:Blood Coagulation Factors; D005338:Fibrin Fibrinogen Degradation Products; D007457:Iodine Radioisotopes; D006493:Heparin
Demi-vie du fibrinogène marqué à l'iode 131 chez les cancéreux. Effets de l'héparine